Form 8-K - Current report:
SEC Accession No. 0001104659-23-062103
Filing Date
2023-05-18
Accepted
2023-05-18 08:08:48
Documents
13
Period of Report
2023-05-18
Items
Item 2.02: Results of Operations and Financial Condition
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K tm2316116d2_8k.htm   iXBRL 8-K 33622
2 EXHIBIT 99.1 tm2316116d2_ex99-1.htm EX-99.1 57875
  Complete submission text file 0001104659-23-062103.txt   278762

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA repl-20230518.xsd EX-101.SCH 3036
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE repl-20230518_lab.xml EX-101.LAB 34476
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE repl-20230518_pre.xml EX-101.PRE 22597
7 EXTRACTED XBRL INSTANCE DOCUMENT tm2316116d2_8k_htm.xml XML 3591
Mailing Address 500 UNICORN PARK WOBURN MA 01801
Business Address 500 UNICORN PARK WOBURN MA 01801 (781) 222-9600
Replimune Group, Inc. (Filer) CIK: 0001737953 (see all company filings)

EIN.: 822082553 | State of Incorp.: DE | Fiscal Year End: 0331
Type: 8-K | Act: 34 | File No.: 001-38596 | Film No.: 23933755
SIC: 2836 Biological Products, (No Diagnostic Substances)